University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
Michael R. Harrison, MD

Michael R. Harrison, MD

Professor, Department of Surgery (Pediatric Surgery), UCSF

Research Summary

As founding director of UCSF's Fetal Treatment Center, Harrison is internationally renowned for his expertise and innovation in pediatric and fetal surgery. Widely regarded as the "father of fetal surgery," Harrison, over the last three decades, concentrated his lab efforts to establish the developmental pathophysiology of correctable birth defects in animal models, and develop and test techniques for fetal intervention (including maternal-fetal anesthesia), prior to clinical application. Now, a decade into the new century, the pioneering spirit continues and manifests in a new direction of innovation-i.e., original thought combined with the first presentation of work that leads to a milestone in the advancement of surgical care. Harrison's current research focuses on pediatric orphan device development, particularly devices employing the use of magnetic force. His most recent work has earned him one of three prestigious stimulus grants awarded by the FDA to fund a pediatric device consortium at UCSF.

Over the last six years, the Harrison lab has explored the use of magnetic force to correct a variety of problems and deformities. They began with the Magnetic Mini-Mover Procedure (3MP) to correct pectus excavatum in children, and tested the Magnimplant device in an FDA-sponsored trial with an FDA-approved IDE. In addition to the Magnetic Mini-Mover, they are continuing to develop and test:

- The Magnamosis device which uses specially designed magnets to create a secure compression anastomosis between any two pieces of intestine

- A magnetic internal-control contraction device to assist in laparoscopic surgery

- The Robo-Implant device, which uses magnetic coupling to activate and lengthen and shorten an internal growing rod for treatment of scoliosis and for limb lengthening.

In the course of developing and testing these magnetic implant treatments, the Harrison Lab most recently began considering the use of magnetic force for the treatment of obstructive sleep apnea. The concept is simple. In the same way that they implant a titanium-encased rare earth magnet on the sternum in patients with pectus excavatum and then, later, the patients use an external magnet orthotic device to gradually pull the 'sunken chest' out, Harrison et al are considering the possibility of implanting a similar magnet on the hyoid bone and letting the patient use an external orthotic magnetic device to pull the hyoid forward and open the airway when sleeping. With this approach the patient is unaffected while awake during the day and the implanted device is essentially invisible.

Under the auspices of the UCSF Pediatric Device Consortium, the mission of the Harrison Lab is to facilitate the development, production, and distribution of pediatric medical devices by:

- Encouraging innovation and connecting qualified individuals with pediatric device ideas with potential manufacturers

- Mentoring and managing pediatric device projects through the development process, including product identification, prototype design, device development, and marketing

- Connecting innovators and physicians to existing Federal and non-Federal resources

- Assessing the scientific and medical merit of proposed pediatric device projects

- Providing assistance and advice as needed on business development, personnel training, prototype development, and post-marketing needs

Selected Publications

  1. Khouri MG, Harrison MR. Look and You Will Find It: Practical Considerations for Improving Multidisciplinary Management of Androgen-Deprivation Therapy-Induced Cardiometabolic Toxicity. J Oncol Pract. 2018 Oct; 14(10):591-593.
    View on PubMed
  2. Bruns NE, Glenn IC, Craner DR, Schomisch SJ, Harrison MR, Ponsky TA. Magnetic compression anastomosis (magnamosis) in a porcine esophagus: Proof of concept for potential application in esophageal atresia. J Pediatr Surg. 2018 Sep 29.
    View on PubMed
  3. Gopalakrishna A, Chang A, Longo TA, Fantony JJ, Harrison MR, Wischmeyer PE, Inman BA. Dietary patterns and health-related quality of life in bladder cancer survivors. Urol Oncol. 2018 Aug 17.
    View on PubMed
  4. Ramalingam S, George DJ, Harrison MR. How we treat brain metastases in metastatic renal cell carcinoma. Clin Adv Hematol Oncol. 2018 Feb; 16(2):110-114.
    View on PubMed
  5. Brousell SC, Fantony JJ, Van Noord MG, Harrison MR, Inman BA. Vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract: an evidence-based review of safety, efficacy, and place in therapy. Core Evid. 2018; 13:1-12.
    View on PubMed
  6. Ashok M, Hung D, Rojas-Smith L, Halpern MT, Harrison M. Framework for Research on Implementation of Process Redesigns. Qual Manag Health Care. 2018 Jan/Mar; 27(1):17-23.
    View on PubMed
  7. Humeniuk MS, Gupta RT, Healy P, McNamara M, Ramalingam S, Harrison M, George D, Zhang T, Wu Y, Armstrong AJ. Platinum sensitivity in metastatic prostate cancer: does histology matter? Prostate Cancer Prostatic Dis. 2018 Apr; 21(1):92-99.
    View on PubMed
  8. Toselli L, Martinez-Ferro M, Cervio G, Kwiat D, Imamura-Ching J, Graves CE, Gaston B, Harrison M. Magnetic Compression Anastomosis (Magnamosis) for Functional Undiversion of Ileostomy in Pediatric Patients. J Laparoendosc Adv Surg Tech A. 2017 Dec; 27(12):1314-1317.
    View on PubMed
  9. Frisoli TM, Nowak R, Evans KL, Harrison M, Alani M, Varghese S, Rahman M, Noll S, Flannery KR, Michaels A, Tabaku M, Jacobsen G, McCord J. Henry Ford HEART Score Randomized Trial: Rapid Discharge of Patients Evaluated for Possible Myocardial Infarction. Circ Cardiovasc Qual Outcomes. 2017 Oct; 10(10).
    View on PubMed
  10. Graves CE, Harrison MR, Padilla BE. Minimally Invasive Fetal Surgery. Clin Perinatol. 2017 Dec; 44(4):729-751.
    View on PubMed
  11. Graves CE, Co C, Hsi RS, Kwiat D, Imamura-Ching J, Harrison MR, Stoller ML. Magnetic Compression Anastomosis (Magnamosis): First-In-Human Trial. J Am Coll Surg. 2017 Nov; 225(5):676-681.e1.
    View on PubMed
  12. Motzer RJ, Jonasch E, Agarwal N, Bhayani S, Bro WP, Chang SS, Choueiri TK, Costello BA, Derweesh IH, Fishman M, Gallagher TH, Gore JL, Hancock SL, Harrison MR, Kim W, Kyriakopoulos C, LaGrange C, Lam ET, Lau C, Michaelson MD, Olencki T, Pierorazio PM, Plimack ER, Redman BG, Shuch B, Somer B, Sonpavde G, Sosman J, Dwyer M, Kumar R. Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 Jun; 15(6):804-834.
    View on PubMed
  13. Moon-Grady AJ, Baschat A, Cass D, Choolani M, Copel JA, Crombleholme TM, Deprest J, Emery SP, Evans MI, Luks FI, Norton ME, Ryan G, Tsao K, Welch R, Harrison M. Fetal Treatment 2017: The Evolution of Fetal Therapy Centers - A Joint Opinion from the International Fetal Medicine and Surgical Society (IFMSS) and the North American Fetal Therapy Network (NAFTNet). Fetal Diagn Ther. 2017; 42(4):241-248.
    View on PubMed
  14. Gopalakrishna A, Longo TA, Fantony JJ, Harrison MR, Inman BA. Physical activity patterns and associations with health-related quality of life in bladder cancer survivors. Urol Oncol. 2017 Sep; 35(9):540.e1-540.e6.
    View on PubMed
  15. Madden-Fuentes RJ, Koontz BF, Harrison MR, George DJ, Davidson B, Gilmore BF, Moul JW, Mantyh C, Peterson AC. How Can We Effectively Address the Medical and Psychological Concerns of Survivors of Pelvic Malignancies? Oncology (Williston Park). 2017 04 15; 31(4):286-94.
    View on PubMed
  16. Bhavsar NA, Harrison MR, Hirsch BR, Creel P, Wolf SP, Samsa GP, Abernethy AP, Simantov R, Borham A, George DJ. Design and Rationale of the Metastatic Renal Cell Carcinoma (MaRCC) Registry: A Prospective Academic and Community-Based Study of Patients With Metastatic Renal Cell Cancer. Cancer Invest. 2017 May 28; 35(5):333-344.
    View on PubMed
  17. Graves CE, Hirose S, Raff GW, Iqbal CW, Imamura-Ching J, Christensen D, Fechter R, Kwiat D, Harrison MR. Magnetic Mini-Mover Procedure for pectus excavatum IV: FDA sponsored multicenter trial. J Pediatr Surg. 2017 Jun; 52(6):913-919.
    View on PubMed
  18. Ramalingam S, Humeniuk MS, Hu R, Rasmussen J, Healy P, Wu Y, Harrison MR, Armstrong AJ, George DJ, Zhang T. Prostate-specific antigen response in black and white patients treated with abiraterone acetate for metastatic castrate-resistant prostate cancer. Urol Oncol. 2017 Jun; 35(6):418-424.
    View on PubMed
  19. Inman BA, Longo TA, Ramalingam S, Harrison MR. Atezolizumab: A PD-L1-Blocking Antibody for Bladder Cancer. Clin Cancer Res. 2017 04 15; 23(8):1886-1890.
    View on PubMed
  20. Armstrong AJ, Humeniuk MS, Healy P, Szmulewitz R, Winters C, Kephart J, Harrison MR, Martinez E, Mundy K, Halabi S, George D. Phase Ib Trial of Cabazitaxel and Tasquinimod in Men With Heavily Pretreated Metastatic Castration Resistant Prostate Cancer (mCRPC): The CATCH Trial. Prostate. 2017 Mar; 77(4):385-395.
    View on PubMed

Go to UCSF Profiles, powered by CTSI